Theriva Biologics Inc

Theriva Biologics Inc. has reported unusual trading activity and filed for an at-the-market offering to raise up to $4 million to support the development of its adenovirus delivery platform.

Theriva Biologics Inc. has successfully closed a $7.5 million public offering to advance its pipeline of cancer therapies, following promising results from its VIRAGE Phase 2b clinical trial.